Intelligence Platform

Patents

Browse 2,465 pharma-relevant patents (US and EP, A61K/A61P) linked to tracked companies. Patent cliff and LOE intelligence for BD teams.

29,054 patents indexed

patent

US 11542302

Modulators of melanocortin receptors for the treatment of depression and anxiety

Arizona Board of Regents on Behalf of the University of Arizona · Granted Tue Jan 03 2023 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Dec 29 2042 00:00:00 GMT+0000 (Coordinated Universal Time)

granted patent

US 11541075

Treatment of arthritis and other musculoskeletal disorders with crosslinked hyaluronic aci

ANIKA THERAPEUTICS, INC. · Granted Tue Jan 03 2023 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Dec 29 2042 00:00:00 GMT+0000 (Coordinated Universal Time)

granted patent

US 11534430

Treatment of asthma and chronic obstructive pulmonary disease with anti-proliferate and an

Lutonix, Inc. · Granted Tue Dec 27 2022 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Dec 22 2042 00:00:00 GMT+0000 (Coordinated Universal Time)

granted patent

US 11534465

Fecal matter for treatment of autoimmune diseases

ACADEMISCH MEDISCH CENTRUM · Granted Tue Dec 27 2022 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Dec 22 2042 00:00:00 GMT+0000 (Coordinated Universal Time)

granted patent

US 11535851

Reagents for treatment of hepatitis B virus (HBV) infection and use thereof

Benitec IP Holdings Inc. · Granted Tue Dec 27 2022 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Dec 22 2042 00:00:00 GMT+0000 (Coordinated Universal Time)

granted patent

US 11529395

Treatment of gastrointestinal bleeding in patients with severe von Willebrand disease by a

Takeda Pharmaceutical Company Limited · Granted Tue Dec 20 2022 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Dec 15 2042 00:00:00 GMT+0000 (Coordinated Universal Time)

granted patent

US 11524013

Treatment of hypercoagulopathy in Cushing's syndrome by administration of glucocorticoid r

Corcept Therapeutics Incorporated · Granted Tue Dec 13 2022 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Dec 08 2042 00:00:00 GMT+0000 (Coordinated Universal Time)

granted patent

US 11524053

Methods and compositions for treatment of angiogenic disorders using anti-VEGF agents

The Regents of the University of California · Granted Tue Dec 13 2022 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Dec 08 2042 00:00:00 GMT+0000 (Coordinated Universal Time)

granted patent

US 11517564

Methods of treatment for cystic fibrosis

Vertex Pharmaceuticals Incorporated · Granted Tue Dec 06 2022 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Dec 01 2042 00:00:00 GMT+0000 (Coordinated Universal Time)

granted patent

US 11512309

Treatment of ophthalmic conditions with angiopoietin-like 7 (ANGPTL7) inhibitors

REGENERON PHARMACEUTICALS, INC. · Granted Tue Nov 29 2022 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Nov 24 2042 00:00:00 GMT+0000 (Coordinated Universal Time)

granted patent

US 11512312

Treatment of Fuchs' endothelial corneal dystrophy

The Board of Regents of the University of Texas System · Granted Tue Nov 29 2022 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Nov 24 2042 00:00:00 GMT+0000 (Coordinated Universal Time)

granted patent

US 11510887

Sobetirome in the treatment of myelination diseases

United States Government as represented by the Department of Veterans Affairs · Granted Tue Nov 29 2022 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Nov 24 2042 00:00:00 GMT+0000 (Coordinated Universal Time)

granted patent

US 11512052

Dihydropyridines for the treatment of cognitive impairment or traumatic brain injury

granted patent

US 11512141

Fibrinogen-like protein 2 (FGL2) monoclonal antibodies and their use in cancer detection a

granted patent

US 11505604

Humanized monoclonal antibodies and methods of use for the diagnosis and treatment of colo

PRECISION BIOLOGICS, INC. · Granted Tue Nov 22 2022 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Nov 17 2042 00:00:00 GMT+0000 (Coordinated Universal Time)

granted patent

US 11504390

Treatment of increased lipid levels with sterol regulatory element binding transcription f

REGENERON PHARMACEUTICALS, INC. · Granted Tue Nov 22 2022 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Nov 17 2042 00:00:00 GMT+0000 (Coordinated Universal Time)

granted patent

US 11505574

Modulation of P53 for the treatment of cancer

The Regents of the University of California · Granted Tue Nov 22 2022 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Nov 17 2042 00:00:00 GMT+0000 (Coordinated Universal Time)

granted patent

US 11505572

Therapeutics for the treatment of glaucoma

Regents of the University of Minnesota · Granted Tue Nov 22 2022 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Nov 17 2042 00:00:00 GMT+0000 (Coordinated Universal Time)

granted patent

US 11497739

Materials and methods for diagnosis, prevention and/or treatment of stress disorders and c

United States Government as represented by the Department of Veterans Affairs · Granted Tue Nov 15 2022 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Nov 10 2042 00:00:00 GMT+0000 (Coordinated Universal Time)

granted patent

US 11497740

Use of Jumonji C demethylase inhibitors for the treatment and prevention of chemotherapy r

The Board of Regents of the University of Texas System · Granted Tue Nov 15 2022 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Nov 10 2042 00:00:00 GMT+0000 (Coordinated Universal Time)

granted patent

US 11497736

Compositions for an orally active 1,2,4-oxadiazole for the treatment of disease

PTC THERAPEUTICS, INC. · Granted Tue Nov 15 2022 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Nov 10 2042 00:00:00 GMT+0000 (Coordinated Universal Time)

granted patent

US 11497725

Treatment for obesity

AXSOME MALTA LTD. · Granted Tue Nov 15 2022 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Nov 10 2042 00:00:00 GMT+0000 (Coordinated Universal Time)

granted patent

US 11492643

Methods and compositions for treatment of a genetic condition

Sangamo Therapeutics, Inc. · Granted Tue Nov 08 2022 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Nov 03 2042 00:00:00 GMT+0000 (Coordinated Universal Time)

granted patent

US 11491212

Subcutaneous administration of modified factor IX polypeptides and treatment of hemophilia

Catalyst Biosciences, Inc. · Granted Tue Nov 08 2022 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Nov 03 2042 00:00:00 GMT+0000 (Coordinated Universal Time)

granted